Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Perspectives

Challenges with managing the high rates of infections seen in patients with AML 2:27
Challenges with managing the high rates of infections seen in patients with AML
Andrius Žučenka • 8 Dec 2023
Managing adverse risk AML: clinical considerations & future outlooks 1:12
Managing adverse risk AML: clinical considerations & future outlooks
Amir Fathi • 21 Nov 2023
The impact of next-generation BTK inhibitors on the lymphoma treatment landscape 0:56
The impact of next-generation BTK inhibitors on the lymphoma treatment landscape
Julie Vose • 28 Nov 2023
Challenges and options for patients with hydroxyurea-resistant PV 1:40
Challenges and options for patients with hydroxyurea-resistant PV
Andrew Kuykendall • 27 Nov 2023
Exciting lymphoma updates to expect at ASH 2023 0:48
Exciting lymphoma updates to expect at ASH 2023
Julie Vose • 28 Nov 2023
ASH 2023: what to look forward to in the MPN space 1:27
ASH 2023: what to look forward to in the MPN space
Andrew Kuykendall • 27 Nov 2023
Novel targets being explored in multiple myeloma and the value of CELMoDs 1:33
Novel targets being explored in multiple myeloma and the value of CELMoDs
Andrew Cowan • 29 Sep 2023
Upcoming novel agents for the treatment of sickle cell disease 1:10
Upcoming novel agents for the treatment of sickle cell disease
Perla Eleftheriou • 24 Oct 2023
Challenges with selecting therapy after failure of frontline treatments in R/R multiple myeloma 2:06
Challenges with selecting therapy after failure of frontline treatments in R/R multiple myeloma
Noopur Raje • 29 Sep 2023
Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy 1:37
Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy
Michele Cavo • 28 Sep 2023
Personalizing treatment in multiple myeloma: approaching patients with t(4;14) and t(11;14) 1:46
Personalizing treatment in multiple myeloma: approaching patients with t(4;14) and t(11;14)
Gareth Morgan • 29 Sep 2023
Defining and treating high-risk multiple myeloma 2:00
Defining and treating high-risk multiple myeloma
Frits van Rhee • 28 Sep 2023
Highlights from IMS 2023: integrating multi-omic technologies & understanding resistance 1:40
Highlights from IMS 2023: integrating multi-omic technologies & understanding resistance
Constantine Mitsiades • 29 Sep 2023
The value of circulating tumor cells for the staging of patients with NDMM 2:42
The value of circulating tumor cells for the staging of patients with NDMM
Bruno Paiva • 29 Sep 2023
Main goals for treating patients with AL amyloidosis: achieving complete hematologic response 1:33
Main goals for treating patients with AL amyloidosis: achieving complete hematologic response
Vaishali Sanchorawala • 29 Sep 2023
Immunotherapy highlights at IMS 2023: bispecific antibodies, CAR-T cells & unanswered questions 2:50
Immunotherapy highlights at IMS 2023: bispecific antibodies, CAR-T cells & unanswered questions
Heinz Ludwig • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals